Alfa Wasserman deal gives Theravance $63.5m plus royalties for velusetrag

Theravance and the private Italian pharmaceutical group Alfa Wassermann have signed an exclusive development and commercialisation agreement worth up to $63.5 million plus royalties from sales for the US company's oral 5-HT4 agonist velusetrag (TD-5108) as a treatment for gastrointestinal motility disorders.